Literature DB >> 34448113

Variability of CYP2C8 Polymorphisms in Three Jordanian Populations: Circassians, Chechens and Jordanian-Arabs.

Sara Abudahab1,2, Nancy Hakooz3, Nuha Tobeh4, Esraa Gogazeh5, Munir Gharaibeh5, Laith Al-Eitan6,7, Malek Zihlif5, Rana Dajani4,8.   

Abstract

CYP2C8 is a member of Cytochrome P450 enzymes system. It plays an important role in metabolizing a wide range of exogenous and endogenous compounds. CYP2C8 is involved in the metabolism of more than 100 drugs, typical substrates include: anticancer agents, antidiabetic agents, antimalarial agents, lipid lowering drugs and many others that constitute 20% of clinically prescribed drugs. Genetic variations of CYP2C8 have been reported with different frequencies in different populations. These genetic polymorphisms can lead to differences in the efficacy and safety of different types of medications metabolized by CYP2C8. The aim of this study was to investigate the allele frequencies of CYP2C8*3 (rs10509681 and rs11572080) and CYP2C8*4 (rs1058930) polymorphisms in three populations living in Jordan; Circassians and Chechens and Jordanian-Arabs and compare those frequencies with other populations. A total of 200 healthy Jordanians, 93 Circassians and 88 Chechens were included in this study. Genotyping of CYP2C8*3 and CYP2C8*4 polymorphisms was done by using polymerase chain reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP). Using the Chi-square test, we found that the prevalence of CYP2C8*3 and *4 among the three populations were significantly different. Moreover, the mutant allele CYP2C8*3 (416A) was only detected in the Jordanian-Arab population with an allele frequency of 0.082, while the mutant allele CYP2C8*4 (792G) was detected with frequencies of 0.065, 0.122, 0.017 in Jordanian-Arabs, Circassians and Chechens, respectively. As our results show, CYP2C8*3 was undetectable in our Circassians and Chechens samples, on the other hand, Circassians had the highest allele frequency of CYP2C8*4 compared to Chechens and Jordanian-Arabs. These genetic variations of the gene encoding the CYP2C8 drug metabolizing enzymes can lead to clinical differences in drug metabolism and ultimately variations in drug effectiveness and toxicities. This study provides evidence for the importance of personalized medicine in these populations and can be the foundation for future clinical studies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adyghe; CYP2C8; Chechens; Circassians; Drug metabolism variability; Minorities; Nokhchiy; Pharmacogenes; Čerkesy

Mesh:

Substances:

Year:  2021        PMID: 34448113     DOI: 10.1007/s10903-021-01264-x

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  39 in total

1.  Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.

Authors:  Umit Yasar; Stefan Lundgren; Erik Eliasson; Anna Bennet; Björn Wiman; Ulf de Faire; Anders Rane
Journal:  Biochem Biophys Res Commun       Date:  2002-11-22       Impact factor: 3.575

2.  Pharmacogenetics.

Authors:  D A EVANS; C A CLARKE
Journal:  Br Med Bull       Date:  1961-09       Impact factor: 4.291

3.  Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.

Authors:  Anne M Filppula; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

4.  Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.

Authors:  Brendan M Johnson; Brendt A Stier; Stephen Caltabiano
Journal:  Clin Pharmacol Drug Dev       Date:  2013-10-22

5.  Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

Authors:  Lauri I Kajosaari; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-10       Impact factor: 4.080

Review 6.  Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.

Authors:  Janne T Backman; Anne M Filppula; Mikko Niemi; Pertti J Neuvonen
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

Review 7.  Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Authors:  Rheem A Totah; Allan E Rettie
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

8.  Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.

Authors:  T S Klose; J A Blaisdell; J A Goldstein
Journal:  J Biochem Mol Toxicol       Date:  1999       Impact factor: 3.642

9.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

10.  Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Authors:  Jacqueline A Gibbons; Michiel de Vries; Walter Krauwinkel; Yoshiaki Ohtsu; Jan Noukens; Jan-Stefan van der Walt; Roelof Mol; Joyce Mordenti; Taoufik Ouatas
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.